Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

Highlights • European ALMA score (E-ALMA) takes into consideration ECOG, WBC and cytogenetics. • It may be used in unfit WHO-defined AML patients treated frontline with azacitidine. • Its design involved 371 unfit AML patients treated in 4 European countries. • AZA may be a good choice for patients...

Full description

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 39; no. 3; pp. 296 - 306
Main Authors Ramos, F, Thépot, S, Pleyer, L, Maurillo, L, Itzykson, R, Bargay, J, Stauder, R, Venditti, A, Seegers, V, Martínez-Robles, V, Burgstaller, S, Récher, C, Debén, G, Gaidano, G, Gardin, C, Musto, P, Greil, R, Sánchez-Guijo, F, Fenaux, P
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.03.2015
Subjects
Acute myeloid leukemia
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - therapeutic use
Azacitidine
Azacitidine - therapeutic use
Elderly
Female
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - mortality
Male
Middle Aged
Prediction
Remission Induction
Retrospective Studies
Score
Survival Rate
Treatment Outcome
Unfit
Validation Studies as Topic
Unfit
Score
Azacitidine
Acute myeloid leukemia
Elderly
Prediction
Online AccessGet full text

Cover

More Information
Summary:Highlights • European ALMA score (E-ALMA) takes into consideration ECOG, WBC and cytogenetics. • It may be used in unfit WHO-defined AML patients treated frontline with azacitidine. • Its design involved 371 unfit AML patients treated in 4 European countries. • AZA may be a good choice for patients with a favorable or intermediate E-ALMA score.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2014.12.013